Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin
Shiraz E-Medical Journal: 9 (1); 42-44
January 1, 2008
Article Type: Case Report
May 1, 2005
September 2, 2007
M. Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin,
Shiraz E-Med J.
Online ahead of Print
Hepatitis B virus asymptomatic carriers should receive treatment in certain conditions, such as prior to chemotherapy and organ transplantation. In these groups interferon alpha has limited efficacy or is even contraindicated. In contrast, lamivudine is highly effective in both preventing of and treat- ment of HBV reactivation in these immunosuppressed patients. Prevention of reactivation has better results than treating reactivation.
Acute Hepatitis B, Acute Leukemia, Immunosuppression.
© 2008, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.